Last $26.35 USD
Change Today +0.21 / 0.80%
Volume 634.7K
MDCO On Other Exchanges
Symbol
Exchange
Munich
NASDAQ GS
As of 5:20 PM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

medicines company (MDCO) Snapshot

Open
$26.37
Previous Close
$26.14
Day High
$26.77
Day Low
$26.17
52 Week High
01/13/14 - $41.28
52 Week Low
04/1/14 - $23.53
Market Cap
1.7B
Average Volume 10 Days
469.8K
EPS TTM
$0.63
Shares Outstanding
65.0M
EX-Date
--
P/E TM
41.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDICINES COMPANY (MDCO)

medicines company (MDCO) Related Businessweek News

No Related Businessweek News Found

medicines company (MDCO) Details

The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Recothrom, a human recombinant thrombin used as an aid to hemostasis; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria, including Acinetobacter species; and ready-to-use formulation of Argatroban for the treatment of thrombosis. Its products under development include Cangrelor, an intravenous small molecule antiplatelet agent for the prevention of platelet activation and aggregation; Oritavancin, an investigational intravenous antibiotic for the treatment of acute bacterial skin related infections; and IONSYS, a pre-registration stage product for the short-term management of acute postoperative pain. The company’s products under development also comprise Fibrocaps, which is used as an aid to stop bleeding during surgery; RPX-602 for the treatment of infections; MDCO-216, a novel biologic product to reverse atherosclerotic plaque development and reduce the risk of coronary events in patients with ACS; Carbavance, an antibiotic agent for the treatment of hospitalized patients with bacterial infections; and ALN-PCSsc, a subcutaneously administered RNA interference therapeutic for the treatment of hypercholesterolemia. In addition, it offers acute care generic products for use in the cardiovascular and neurocritical care; and promotes BRILINTA, an oral tablet antiplatelet medicine. The company has collaborations with Alnylam Pharmaceuticals, Inc. and AstraZeneca LP. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.

571 Employees
Last Reported Date: 03/3/14
Founded in 1996

medicines company (MDCO) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $793.3K
President, Chief Financial Officer, Treasurer...
Total Annual Compensation: $569.3K
Chief Accounting Officer and Senior Vice Pres...
Total Annual Compensation: $398.2K
Compensation as of Fiscal Year 2013.

medicines company (MDCO) Key Developments

The Medicines Company Presents at Goldman Sachs 35th Annual Global Healthcare Conference, Jun-10-2014 01:20 PM

The Medicines Company Presents at Goldman Sachs 35th Annual Global Healthcare Conference, Jun-10-2014 01:20 PM. Venue: Terranea Resort in Rancho Palos Verdes, 100 Terranea Way, Los Angeles, California, United States. Speakers: Glenn P. Sblendorio, President, Chief Financial Officer, Treasurer and Director.

The Medicines Company Announces Results from SOLO I Phase 3 clinical trial

The Medicines Company announced the publication of the results from the SOLO I Phase 3 clinical trial of ORBACTIV(TM) (oritavancin), an investigational intravenous antibiotic treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI), in the New England Journal of Medicine. The publication reported that a single 1,200 mg intravenous dose of ORBACTIV(TM) was non-inferior to twice-daily intravenous dosing of vancomycin given for 7 to 10 days in patients with ABSSSI caused or suspected to be caused by Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA).

The Medicines Company Presents at Jefferies 2014 Global Healthcare Conference, Jun-02-2014 09:00 AM

The Medicines Company Presents at Jefferies 2014 Global Healthcare Conference, Jun-02-2014 09:00 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Clive A. Meanwell, Chairman and Chief Executive Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDCO:US $26.35 USD +0.21

MDCO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $76.87 USD +0.76
CryoLife Inc $9.07 USD +0.10
Eli Lilly & Co $63.72 USD +0.08
GlaxoSmithKline PLC 1,555 GBp -2.00
Medicure Inc C$2.45 CAD +0.08
View Industry Companies
 

Industry Analysis

MDCO

Industry Average

Valuation MDCO Industry Range
Price/Earnings 77.1x
Price/Sales 2.4x
Price/Book 1.9x
Price/Cash Flow 76.9x
TEV/Sales 1.5x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDICINES COMPANY, please visit www.themedicinescompany.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.